Skip to content

Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment

Comparative Evaluation of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Treatment of 2/3-walled Intrabony Defects in Chronic Periodontitis Subjects: a Randomized Controlled Clinical Trial

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02516111
Enrollment
120
Registered
2015-08-05
Start date
2014-09-30
Completion date
2015-05-31
Last updated
2015-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

The present study is designed as a single-centre, randomized, controlled clinical trial to evaluate and compare the clinical efficacy of autologous PRF, 1% alendronate (ALN) and 1.2% atorvastatin (ATV) gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis.

Detailed description

Background: Platelet-rich fibrin (PRF) is a second-generation platelet concentrate which releases various growth factors that promote tissue regeneration. Alendronate and Atorvastatin are known to inhibit osteoclastic bone resorption and were proposed to have osteostimulative properties by causing osteoblast differentiation in vivo and in vitro as shown by an increase in matrix formation. The aim of the present study is to evaluate and compare the efficacy of autologous PRF, 1% alendronate and 1.2% atorvastatin gel placement with open flap debriedement in treatment of intrabony defects in patients with chronic periodontitis. Methods: 120 CP subjects with IBD ≥3 mm deep and probing depth (PD) ≥5 mm, following scaling and root planing (SRP), were categorized into four treatment groups: 1) OFD 2) OFD with PRF 3) OFD with 1% ALN gel and 4) OFD with 1.2% ATV gel. Clinical parameters including site specific plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD) and relative attachment level (RAL) as well as percentage radiographic intrabony defect depth reduction (DDR) were recorded at baseline before surgery and 9 months post-operatively.

Interventions

Oral prophylaxis followed by Open flap debridement (OFD)

BIOLOGICALOFD with PRF

Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect

DRUGOFD with ALN

Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect

DRUGOFD with ATV

Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect

Sponsors

Government Dental College and Research Institute, Bangalore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy patients with PDs ≥5mm or CALs ≥4 to 6mm and vertical bone loss ≥3 mm on intraoral periapical radiographs with no history of periodontal therapy or use of antibiotics in the preceding 6 months were included

Exclusion criteria

* Patients with a known systemic disease * Known or suspected allergy to the ALN/ bisphosphonates or ATV/statin group * On systemic ALN/ bisphosphonates or ATV/statin group * With aggressive periodontitis * Who used tobacco in any form * Alcoholics * Immunocompromised patients * And pregnant or lactating females were excluded from the study

Design outcomes

Primary

MeasureTime frame
defect depth reduction (DDR)Change from baseline to 9 months

Secondary

MeasureTime frame
change in clinical attachment level (CAL)Change from baseline to 9 months
change in probing pocket depths (PPD)Change from baseline to 9 months
change in plaque index (PI)Change from baseline to 9 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026